Directing NIMH: Morphing Materialist Madmen - Examining Medicine
NIMH announced its new director earlier this year. He seems to be the love child of a couple of older gents in his profession. We can expect the usual: announcements of non-breakthroughs sporadically, waiting for progress in plugged drug-development pipelines usually, and watching while rivers of cash roar past always. NIMH is still pushing RDoC, the New Coke of psychiatry paradigms, which should yield several promising-yet-ultimately-fizzling biomarkers of schizophrenia per year, more certainty that autism isn’t caused by anything, and the discovery that there aren’t just four kinds of depression, as a recent fMRI study showed, but 16, maybe 32. And genomes, many genomes, each one as significant as